Clinical Trials

Breast Neoplasms

NCT01251900 2026-04-14

BRCA Mutations in Latinas

Completed

266 enrolled

BreastGenitourinaryGynecologicLymphoidThoracic

Breast Neoplasms

NCT01441089 2026-04-14

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

Recruiting

1,100 enrolled

Breast Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

NCT02595957 2026-04-14

Genomic Services Research Program

Recruiting

5,000 enrolled

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms

NCT03412877 2026-04-14

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT00310180 2026-04-13

TAILORx

Phase 3 Active not recruiting

10,273 enrolled 14 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT01272037 2026-04-13

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

5,018 enrolled 14 charts

Carcinoma, Intraductal, Noninfiltrating

NCT01327781 2026-04-13

Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer

62 enrolled

Breast Neoplasms

NCT01351909 2026-04-13

Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

35 enrolled

Breast Neoplasms

NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

94 enrolled

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT02311933 2026-04-13

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

81 enrolled 9 charts

Breast Neoplasms

NCT02398773 2026-04-13

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

99 enrolled

HER2/Neu Negative

NCT02453620 2026-04-13

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

BreastOther solid neoplasm

57 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 2 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02883062 2026-04-13

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

67 enrolled 16 charts

Phase 3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02954874 2026-04-13

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

1,155 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03598257 2026-04-13

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

300 enrolled

Inflammatory Breast Neoplasms

NCT04052555 2026-04-13

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

42 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04090398 2026-04-13

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

BreastDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmPlasma cellThoracic

70 enrolled

BreastOther neoplasm

Anatomic Stage IV Breast Cancer AJCC v8

NCT04314401 2026-04-13

National Cancer Institute "Cancer Moonshot Biobank"

Active not recruiting

1,600 enrolled

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04345913 2026-04-13

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

Phase 1/2 Active not recruiting

24 enrolled 24 charts

Triple Negative Breast Neoplasms

NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

BreastGenitourinaryGynecologicOther solid neoplasmThoracic

74 enrolled

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT04550494 2026-04-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

BreastGastrointestinalGenitourinaryGynecologic

36 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT04704661 2026-04-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

BreastGastrointestinalGynecologicHead & NeckSarcoma

51 enrolled

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04955808 2026-04-13

Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

Suspended

2,400 enrolled

BreastGastrointestinalGenitourinaryPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Multiple Myeloma, Prostatic Neoplasms

NCT05111561 2026-04-13

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Phase 1 Suspended

42 enrolled

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05372640 2026-04-13

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

45 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05422794 2026-04-13

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

57 enrolled

Triple Negative Breast Neoplasms

NCT05673200 2026-04-13

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

32 enrolled

Triple Negative Breast Neoplasms

NCT05941520 2026-04-13

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

80 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06184750 2026-04-13

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

200 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06195306 2026-04-13

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

66 enrolled